INTRODUCTION
============

Non-small-cell lung carcinoma (NSCLC) is a type of epithelial lung cancer, constituting \~80% to 90% of all lung cancers ([@b18-molce-42-804]; [@b20-molce-42-804]). NSCLC is classified into three types: lung adenocarcinoma (LUAD), squamous cell carcinoma, and large cell carcinoma. LUAD accounts for approximately 30% of lung cancers ([@b9-molce-42-804]). *Serine/threonine kinase 11* (*STK11*), also known as *liver kinase B1* (*LKB1*), is a major tumor suppressor gene in lung cancers. Particularly, *STK11* is the most inactivated tumor suppressor gene in NSCLC ([@b4-molce-42-804]; [@b5-molce-42-804]; [@b7-molce-42-804]). Although *STK11* inactivation (i.e., loss-of-function mutation) occurs in \~30% of LUAD ([@b13-molce-42-804]), its role in cancer progression has yet to be elucidated ([@b8-molce-42-804]).

In previous studies, we found target genes and drugs with *STK11* mutation-specific anticancer efficacy in lung cancer cell lines ([@b10-molce-42-804]; [@b13-molce-42-804]). The expression of *phosphodiesterase-4D* (*PDE4D*) was found to be upregulated in both lung cancer cell lines and tissue samples harboring *STK11* homogeneous mutations. Knockdown of *PDE4D* gene expression and chemical inhibition of *PDE4D* protein enhanced the anticancer efficacy in *STK11*-mutant cell lines compared with other lung cancer cell lines ([@b10-molce-42-804]). Drugs inhibiting *ATPase Na+/K+ Transporting Subunit Alpha 1* (*ATP1A1*) also showed selective efficacy in *STK11*-mutant lung cancer cell lines ([@b13-molce-42-804]). In the present study, we systematically analyzed the cancer transcriptome to further identify *STK11*-specific gene expression signatures in lung cancers. We compared the gene expression profile of *STK11* loss-of-function cells (homozygous mutations) and *STK11* wild type cells from the LUAD cell line panel and tissue samples. The expression of several genes exhibited significant sensitivity and specificity to the *STK11* mutation. Particularly, the expression of *Enolase 3* (*ENO3*) was altered by the loss or recovery of *STK11* gene expression.

*Enolase* (*ENO*), also known as phosphopyruvate dehydratase, is a metalloenzyme that catalyzes the transformation of *2-phosphoglycerate* (2-PG) to *phosphoenolpyruvate* (PEP) during glycolysis ([@b11-molce-42-804]). The three isoforms of *ENO*s in mammalian cells include: *α* or *non-neuronal enolase* (*NNE*), *γ* or *neuron-specific enolase* (*NSE*), and *β* or *muscle-specific enolase* (*MSE*) ([@b17-molce-42-804]; [@b19-molce-42-804]). They are cytoplasmic enzymes involved in glycolysis and gluconeogenesis ([@b16-molce-42-804]). Specially, the expression of *ENO1* was highlighted in small-cell lung carcinoma (SCLC) tissues, suggesting its association with cancer cell migration ([@b11-molce-42-804]; [@b15-molce-42-804]). The increased expression of *ENO2* gene has also been reported in NSCLC ([@b11-molce-42-804]; [@b12-molce-42-804]). However, the role and function of *ENO3* in cancer have yet to be elucidated. Here, we present the results of *ENO3* regulation by the *STK11* gene expression via *STK11* mutation-specific transcriptome analysis. The therapeutic potential of *ENO3* as the *STK11* mutation-specific target was also investigated. This study extends our knowledge of *STK11* mutation-driven cancer progress, and contributes to the development of new targeted therapies.

MATERIALS AND METHODS
=====================

Data acquisition
----------------

DNA microarray gene expression data of 47 LUAD cell lines were obtained from the Cancer Cell Line Encyclopedia (CCLE) ([@b2-molce-42-804]). mRNA expression levels obtained using Affymetrix U133 plus 2.0 arrays were represented as log~2~-transformed value after robust multichip average (RMA) normalization. The expression ranges are from 3 to 15 and the average expression is 7.5. Among 54,613 gene probes, the data available for the 15,080 gene probes in \> 50% of selected LUAD cell lines were used in the present analysis. *STK11* loss-of-function cell lines were defined by analyzing the accompanying exome sequencing data ([Supplementary Table 1](#s1-molce-42-804){ref-type="supplementary-material"}). For the analysis of *STK11*-dependent gene expression, we retrieved the DNA microarray data of two *STK11* mutant, parental A549 cell lines and two *STK11*-recovered A549 cell lines (GSE6135) from Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) ([@b6-molce-42-804]). Gene expression data were obtained using Agilent Homo sapiens 44k custom array and represented as log~2~ scale after normalization by locally weighted scatterplot smoothing (LOWESS). In addition, 230 patient tissue-based gene expression and exome sequencing data of LUAD were obtained from The Cancer Genome Atlas (TCGA) ([@b3-molce-42-804]). The RNA-seq expression level of each gene was represented with log~2~-transformed through upper quartile normalized RSEM (RNA-Seq by Expectation Maximization).

Sensitivity and specificity
---------------------------

To identify differentially expressed genes between *STK11* mutant and wild-type cell lines, we used fold change and *t*-test *P* values. The fold change is defined as the difference between the averages of two compared groups. For statistical significance, we calculated *P* values from the *t*-statistic. To determine the selective association between gene expression and *STK11* mutation, we also calculated the enrichment score using the odds ratio between the observed odds and the expected odds. The observed and the expected odds are defined as the ratio of cell lines with over threshold (fold change \> 1) among *STK11* mutant LUAD and among all LUAD cell lines, respectively. The statistical confidence of an odds ratio was calculated using Fisher's exact test. Statistical analysis was performed using Perl (ver. 5.30.0; <http://www.perl.org/>).

Cell-based *in vitro* assays
----------------------------

A549, H23, H1993, and H322M cells were obtained from the National Institutes of Health, National Cancer Institute (NCI, USA). HCC-827 and H1975 cells were obtained from the American Type Culture Collection (ATCC, USA). The *STK11*-recovered cells from three parental cell lines (A549-*STK11*, H23-*STK11*, and H1993-*STK11*) were established in our laboratory ([@b13-molce-42-804]). *STK11* mutant and wild-type cell lines were cultured in RPMI 1640 (HyClone Laboratories, USA) supplemented with 10% fetal bovine serum (HyClone Laboratories) and 1% antibiotics (Thermo Fisher Scientific, USA) according to institutional laboratory safety guidelines. The *STK11*-recoverd cell lines were cultured in the same medium after supplementation with 1 μg/ml puromycin. The cells were maintained at 37°C in a 5% CO~2~ incubator and subcultured at 80% to 90% confluence. The media were changed every 2 to 3 days. A total of 1 to 3 × 10^5^ cells per well were seeded on a 6-well culture plate for monolayer cell cultures for 3 days.

For siRNA transfection, we experimented with 10 nmol/L target siRNAs of NC (negative control), PLK1 (positive control), and *ENO3* (Thermo Fisher Scientific, On-Target Plus SmartPool; GE Dharmacon, USA) ([@b21-molce-42-804]). Cells were seeded in a 96-well plate (Corning, USA) at an optimized density of 2,000 to 8,000 cells/well. After 72 h of seeding, the viability was measured using the CellTiter-Blue for Cell Viability Assay (Promega, USA). Simultaneously, cells were stained with DAPI and single cells were counted with Gen5^TM^ software (BioTek Instruments, USA).

Quantitative real-time polymerase chain reaction analysis
---------------------------------------------------------

Total RNA was extracted in 6-well plates using TRIzol. Synthesis of cDNA and polymerase chain reaction (PCR) amplification were carried out with the SuperScript One-step RT-PCR Platinum Taq Kit (Invitrogen, USA). The gene expression of *ENO1*, *ENO2*, and *ENO3* was quantified via real-time PCR using specific primer sets targeting *ENO1* (Hs00157360_m1, TaqMan), *ENO2* (Hs00361415_m1, TagMan), and *ENO3* (Hs01093275_m1, TaqMan), respectively, and the reference gene *GAPDH* (Hs02786624_g1, TagMan) ([@b1-molce-42-804]; [@b14-molce-42-804]). Quantitative real-time PCR (RT-qPCR) were carried out on an Applied Biosystems 7500 (Thermo Fisher Scientific) using a TaqMan real-time detection protocol. The delta cycle threshold (dCt) corresponds to the cycle threshold (Ct) values for *ENO1*, *ENO2*, and *ENO3* RNA expression normalized to those for RNA expression of the internal control *GAPDH*. For intuitive interpretation, -dCt is used so as that the higher values indicate a higher normalized target gene expression.

RESULTS AND DISCUSSION
======================

Analysis of *STK11*-associated gene expression in LUAD cell lines
-----------------------------------------------------------------

DNA microarray data of 47 LUAD cell lines were analyzed to identify the gene expression markers associated with *STK11* mutations ([Fig. 1](#f1-molce-42-804){ref-type="fig"}). We compared the differences in gene expression between nine cell lines with *STK11* loss-of-function mutations ([Supplementary Table 1](#s1-molce-42-804){ref-type="supplementary-material"}) and 38 *STK11* wild-type cell lines based on fold change and odds ratio. The fold change reflects the sensitivity of the gene expression in *STK11* mutant cells against *STK11* wild-type cells, while the odds ratio quantifies the specificity (i.e., exclusiveness) of a gene expression in *STK11*-mutant cell lines compared with other cell lines (see Materials and Methods section for details). As a result, 222 gene probes (sensitive hits) were significantly (*P* \< 0.01) over- or under-expressed (\> 2-fold change) in *STK11* mutation cells in LUAD, while the expression of 71 gene probes (specific hits) exhibited significantly (*P* \< 0.01) exclusive expression (\> 2-odds ratio). Since no general correlation was observed between sensitivity and specificity of gene expression, the selection of common hits based on these two measures provided unique gene expression signatures (or biomarkers) of *STK11* mutant cancer cells. A total of 11 gene probes satisfied both sensitivity and specificity of the expression associated with *STK11* loss-of-function mutations ([Fig. 1](#f1-molce-42-804){ref-type="fig"}). These 11 genes were identified from diverse functional classes and their functional or signaling aspects have never been reported in connection with the suppressive role of *STK11* in the cancer progression.

We further investigated the association of these 11 gene expression profiles associated with *STK11* mutations using the RNA sequencing data of patient-derived tumor tissue samples. The gene expression was statistically compared between 40 *STK11*-mutant and 190 wild-type LUAD samples from the TCGA database (see Materials and Methods section). Among the 11 genes selected from the analysis of cell line data in [Figure 1](#f1-molce-42-804){ref-type="fig"}, the expression of *ENO3* and *TTC39C* genes was found to be significantly up-regulated in *STK11* mutant tissue samples ([Fig. 2A](#f2-molce-42-804){ref-type="fig"}). Down-regulation of *LGALS3* and *MAML2* genes in *STK11*-mutant cell lines was also confirmed in patient-derived LUAD samples. Particularly, the differential expression of the *ENO3* gene in *STK11*-mutant and wild type samples was greater than 2-fold in tissue samples, displaying a minimal level of the *ENO3* gene expression in most of the *STK11* wild-type LUAD samples.

*STK11*-dependent *ENO3* gene expression
----------------------------------------

The gene expression of *ENO3, TTC39C, LGALS3*, and *MAML2* was consistently up-or down-regulated in both *STK11*-mutant cell lines and tissue samples of LUAD. We thus investigated the changes in their gene expression based on the recovery of *STK11* function in the *STK11*-mutant LUAD cell line (A549). DNA microarray data of *STK11*-mutant (loss-of-function) A549 and *STK11*-recovered A549 cell lines were retrieved from the GEO database (GSE6135). Since the gene expression data of *TTC39C* were not available in the dataset, we only analyzed the differential expression of *ENO3, LGALS3*, and *MAML2* in *STK11*-mutant and *STK11*-recovered A549 cells ([Fig. 2B](#f2-molce-42-804){ref-type="fig"}). While the expression of *LGALS3* and *MAML2* was not changed by *STK11* functional recovery, the *ENO3* expression was greatly reduced in *STK11*-recovered A549 cells compared with *STK11*-mutant A549 cells suggesting that the *ENO3* over-expression in both *STK11*-mutant LUAD cell lines and tissue samples was a direct the consequence of *STK11* loss-of-function.

Although *ENO1* and *ENO2* have been widely studied in cancer context ([@b11-molce-42-804]; [@b12-molce-42-804]; [@b15-molce-42-804]), the role of *ENO3* in cancers has yet to be fully elucidated. In our analysis of CCLE dataset, the expression of *ENO1* and *ENO2* did not show any difference between *STK11*-mutant and -wild type cell lines ([Fig. 3A](#f3-molce-42-804){ref-type="fig"}). To further confirm the exclusive dependence of *ENO3* overexpression on *STK11* loss-of-function, we measured the mRNA levels of *ENO1*, *ENO2*, and *ENO3* in diverse cell lines with/without *STK11* function ([Fig. 3B](#f3-molce-42-804){ref-type="fig"}). As a result, only the expression of *ENO3* exhibited exclusive sensitivity to *STK11* functional status. In these qPCR experiments, cell lines harboring *STK11* mutations (A549, H23, and H1993) displayed \> 2-fold overexpression of the *ENO3* mRNAs compared with *STK11* wild-type cell lines (H322M, HCC827, and H1975). Recovery of *STK11* function by the three *STK11*-mutant cell lines reduced the *ENO3* gene expression, although the statistical significance was relatively weak ([Fig. 3B](#f3-molce-42-804){ref-type="fig"}). These qPCR validations strongly suggested that *STK11* loss-of-function mutation directly induced the overexpression of *ENO3* in LUAD cells.

Selective anticancer effect of *ENO3* knockdown on *STK11*-mutant cancer cells
------------------------------------------------------------------------------

The observation of *ENO3* overexpression under *STK11* loss-of-function mutations implies that *ENO3* might be a selective anticancer target in *STK11*-mutant cancer. We thus investigated the anticancer effect of *ENO3* knockdown by siRNAs. In case of *STK11* wild-type LUAD cell lines (H322M, HCC827, and H1975), the siENO3 treatment resulted in less than 5% inhibition of cell proliferation in 72 h *in vitro* assays ([Fig. 4A](#f4-molce-42-804){ref-type="fig"}). However, the anti-proliferative effect of siENO3 was increased on *STK11*-mutant cell lines (A549, H23, and H1993). The cell viability results were consistent with the cell proliferation assay ([Fig. 4B](#f4-molce-42-804){ref-type="fig"}). The viability of *STK11*-mutant cells was more sensitive to siENO3 treatment than *STK11* wild-type cells. We further compared the efficacy of siENO3 in *STK11*-mutant cell lines compared with the corresponding cell lines with *STK11* functional recovery ([Figs. 4C and 4D](#f4-molce-42-804){ref-type="fig"}). In both of cell proliferation and viability measures, STK11-recovered cells were less sensitive to siENO3 treatment than the parental mutant cells in H23 and H1993 cases. However, A549 cells showed inconsistent patterns between cell proliferation and viability assays, implying the existence of a cell line-specific effect of the STK11 recovery in cancer cells. Overall, these results in [Figure 4](#f4-molce-42-804){ref-type="fig"} suggest that *ENO3*, induced by *STK11* loss-of-function, might play a selective role in the development of targeted therapies against LUAD cell lines carrying *STK11* mutations as an effective clinical biomarker.
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![Analysis of gene expression associated with *STK11* mutations\
A total of 15,080 gene probes were plotted to determine *STK11* sensitive vs. *STK11* specific expression in the CCLE dataset. The sensitivity (i.e., log~2~ fold-change) was determined based on the gene expression ratio in nine *STK11*-mutant cell lines compared with 38 *STK11* wild-type cell lines. The specificity (i.e., log~2~ odds ratio) of a gene expression was based on the ratio of the observed odds in *STK11*-mutant cell lines over the expected odds in all cell lines. Orange circles represent the 71 *STK11*-specific gene probes with \> 2 odds ratio (Fisher's exact test, *P* \< 0.01) in *STK11*-mutant cell lines. Blue circles represent the 222 *STK11*-sensitive gene probes with \> 2 fold change (Student's *t*-test, *P* \< 0.01) in *STK11*-mutant cell lines. Filled red circles represent 11 common hits of specific (orange) and sensitive (blue) gene probes.](molce-42-804f1){#f1-molce-42-804}

![*STK11*-specific expression of selected genes in LUAD tissue samples and *STK11*-recovered model cell line\
(A) Differential expression of genes plotted using LUAD tissue samples retrieved from TCGA. A total of 230 samples were classified into *STK11* mutants (40 samples) and wild types (190 samples), and their gene expression (log~2~-transformed upper quartile values) was analyzed. Student's *t*-test for LGALS3 and Wilcoxon rank-sum test for others were used to test statistical significance. (B) Differential gene expression was analyzed in *STK11*-mutant A549 cells and *STK11*-recovered A549 cells retrieved from GEO (GSE6135). Student's *t*-test was used to test statistical significance. Error bars indicate SD.](molce-42-804f2){#f2-molce-42-804}

![Expression of ENO gene family in DNA microarray data and qPCR experiment using LUAD cell lines\
(A) Comparison of *ENO* family gene expression (ENO1: 201231_s\_at, ENO2: 201313_at, and ENO3: 204483_at) between nine *STK11*-mutant and 38 *STK11* wild-type cell lines in the CCLE dataset. Wilcoxon rank-sum test for ENO3 and Student's *t*-test for others were used to test statistical significance. (B) Experimental validation (qPCR) of *ENO* family gene expression in *STK11* wide-type cell lines (H322M, HCC827, and H1975), *STK11*-mutant parental cell lines (A549, H23, and H1993) and *STK11*-restored cell lines. The expression level of GAPDH was observed to be varied within SD \< 1 among 9 cell lines. Student's *t*-test was used to test statistical significance. Error bars indicate SD.](molce-42-804f3){#f3-molce-42-804}

![*STK11* mutation-dependent anticancer efficacy of *ENO3* gene knockdown\
Average variation in cell proliferation (A) and cell viability (B) of *STK11* wild-type cell lines (H322M, HCC827, and H1975) and mutant cell lines (A549, H23, and H1993) by the *ENO3* gene knockdown using siRNAs. Comparative changes in cell proliferation (C) and cell viability (D) in *STK11*-mutant parental cells and *STK11* recovered cells by the *ENO3* gene knockdown. Cell proliferation was measured based on the direct cell count in the well. Cell viability was measured using CellTiter Blue assay (see the Materials and Methods section for detail). All y-axes represent percentage of cell proliferation or cell viability divided by an average of negative control. Student's one-tailed *t*-test was used to test statistical significance. Error bars indicate SD.](molce-42-804f4){#f4-molce-42-804}
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